Search Results 671-680 of 18372 for alopecia

1. A Study of SC-006 in Subjects With Advanced Cancer - Mayo Clinic

   Recovery to Grade 1 of any clinically significant toxicity (excluding alopecia and peripheral neuropathy) prior to initiation of study drug administration.

2. Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia - Mayo Clinic

   Persistent clinically significant ≥ Grade 2 toxicities from previous chemotherapy (excluding alopecia, nausea, fatigue, anemia, and liver function tests [as ...

3. Cosmetic surgery - Doctors & Departments - Mayo Clinic

   ... Alopecia areata, Oral ulcerative condition, Facial volume loss, Vulvar disorder. Show more areas of focus for Alison J. Bruce, M.B., Ch.B.

4. Study to Compare the Safety and Effectiveness of Treatment Combinations in Patients with Recurrent Ovarian Cancer - Mayo Clinic

   Note: Patient with Grade ≤ 2 neuropathy or alopecia is an exception to this criterion and may qualify for the study. Patient has a known diagnosis of ...

5. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   All acute toxic effects of any prior antitumor therapy resolved to Grade ≤1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 ...

6. A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination with Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14) - Mayo Clinic

   Toxicities due to prior therapy must be stable and recovered to ≤ Grade 1 (except for clinically non-significant toxicities, such as alopecia). Age 18 or ...

7. Sirolimus (oral route) - Side effects & dosage - Mayo Clinic

   Sirolimus is used together with other medicines to prevent the body from rejecting a transplanted kidney. It belongs to a group of medicines known as ...

8. Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Using Nivolumab with or without Varlilumab - Mayo Clinic

   Patients who have not recovered to grade 1 or less from any adverse events due to agents administered more than 4 weeks earlier (excluding alopecia).

9. Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck - Mayo Clinic

   Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the ...

10. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

    All prior treatment- related toxicities must be NCI-CTCAE v4 ≤ Grade 1 (except alopecia (permitted at any grade) and peripheral neuropathy (permitted at ...